NCT05675319 2026-01-05
AlloRelapseMM
Universitätsklinikum Hamburg-Eppendorf
Phase 3 Terminated
Clinical Trials
9 trialsNCT03769181 2025-09-23
A Study of Isatuximab-based Therapy in Participants With Lymphoma
Sanofi
Phase 1/2 Terminated
NCT03860844 2025-09-09
ISAKIDS
Sanofi
Phase 2 Terminated
NCT03530683 2024-09-03
A Clinical Trial to Learn About the Study Medicine Called Maplirpacept (PF-07901801), Alone and When Used in Combination With Other Medicines to Treat Participants With Advanced Hematological Malignancies, Including Lymphoma, Leukemia and Multiple Myeloma
Pfizer
Phase 1 Terminated
NCT05284032 2024-07-31
A Pilot Trial Using Isatuximab to Overcome Platelet Transfusion Refractoriness in Human Leukocyte Antigen Allo-Immunized Patients (SuppCare 001)
University of Virginia
Phase EARLY_PHASE1 Terminated
NCT04912427 2024-02-09
Isatuximab, Velcade, and Dexamethasone in Patients With Multiple Myeloma and Severe KIDNEY Disease
Washington University School of Medicine
Phase 1 Terminated
NCT03637764 2023-07-10
Safety, Preliminary Efficacy and PK of Isatuximab (SAR650984) Alone or in Combination With Atezolizumab in Patients With Advanced Malignancies
Sanofi
Phase 1/2 Terminated
NCT03367819 2022-05-16
Isatuximab in Combination With REGN2810 (Cemiplimab) in Patients With Advanced Malignancies
Sanofi
Phase 1/2 Terminated
NCT02999633 2022-03-21
ISLAY
Sanofi
Phase 2 Terminated